Arcutis has announced positive topline results from the ARRECTOR pivotal phase 3 trial evaluating roflumilast foam 0.3% for the treatment of adults and adolescents with scalp and body psoriasis, according to a company press release.
“We are excited to share these topline results of roflumilast foam, a once-daily non-steroidal treatment option that was designed to overcome limitations of traditional creams and ointments for hair-bearing areas of the body,” Patrick Burnett, MD, PhD, chief medical officer at Arcutis, said. “These pivotal phase 3 results demonstrate the strong